Want to see GKOS full AI Analyst Report?

Glaukos (GKOS) Stock Forecast & Price Target

434 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GKOS Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Glaukos

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GKOS Stock 12 Month Forecast

Average Price Target

$197.58

▲(9.42% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $197.58 with a high forecast of $225.00 and a low forecast of $172.00. The average price target represents a 9.42% change from the last price of $180.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","118":"$118","154":"$154","190":"$190","226":"$226"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$225.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":197.58333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$197.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":172,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$172.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,118,154,190,226],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.17,167.92615384615382,172.6823076923077,177.43846153846152,182.19461538461536,186.95076923076923,191.70692307692306,196.46307692307693,201.21923076923076,205.9753846153846,210.73153846153846,215.4876923076923,220.24384615384616,{"y":225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.17,165.8171794871795,168.46435897435896,171.11153846153846,173.75871794871793,176.40589743589743,179.05307692307693,181.7002564102564,184.3474358974359,186.99461538461537,189.64179487179487,192.28897435897437,194.93615384615384,{"y":197.58333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.17,163.84923076923076,164.52846153846153,165.2076923076923,165.88692307692307,166.56615384615384,167.2453846153846,167.92461538461538,168.60384615384615,169.28307692307692,169.9623076923077,170.64153846153846,171.32076923076923,{"y":172,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":83.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.57,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.17,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$225.00

Average Price Target$197.58

Lowest Price Target$172.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Stephan

Stifel Nicolaus

$190

Buy

5.22%

Upside

Reiterated

10/16/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK), Crescent Biopharma (NASDAQ: CBIO) and Glaukos (NYSE: GKOS)

Anthony Petrone

Mizuho Securities

$185

Buy

2.45%

Upside

Reiterated

10/13/26

Glaukos price target raised to $190 from $185 at MizuhoGlaukos price target raised to $190 from $185 at Mizuho

Adam Maeder

Piper Sandler

$195

Buy

7.99%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Glaukos (NYSE: GKOS)

Ryan Zimmerman

BTIG

$202→$205

Buy

13.53%

Upside

Reiterated

10/12/26

Glaukos price target raised to $205 from $202 at BTIGGlaukos price target raised to $205 from $202 at BTIG

Michael Sarcone

Jefferies

$210

Buy

16.30%

Upside

Reiterated

09/22/26

Glaukos price target raised to $210 from $190 at JefferiesGlaukos price target raised to $210 from $190 at Jefferies

Joanne Wuensch

Citi

$188→$225

Buy

24.61%

Upside

Reiterated

08/14/26

Glaukos (GKOS) Gets a Buy from Citi

Allen Gong

J.P. Morgan

$200

Buy

10.76%

Upside

Reiterated

08/04/26

Glaukos (GKOS) Gets a Buy from J.P. Morgan

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), Viking Therapeutics (NASDAQ: VKTX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

$180→$215

Buy

19.07%

Upside

Reiterated

07/30/26

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$138→$178

Buy

-1.42%

Downside

Assigned

07/30/26

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

David Saxon

Needham

$150→$201

Buy

11.31%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Glaukos (NYSE: GKOS) and MannKind (NASDAQ: MNKD)

Patrick Wood

UBS

$150→$172

Hold

-4.75%

Downside

Reiterated

07/30/26

Glaukos assumed with Neutral from Buy at UBSGlaukos assumed with Neutral from Buy at UBS

Yi Chen

H.C. Wainwright

$168→$195

Buy

7.99%

Upside

Reiterated

07/30/26

Glaukos price target raised to $195 from $168 at H.C. WainwrightGlaukos price target raised to $195 from $168 at H.C. Wainwright

David Roman

Goldman Sachs

$153

Buy

-15.27%

Downside

Reiterated

05/25/26

Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)

Mason Carrico

Stephens

$115→$145

Buy

-19.70%

Downside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Stephan

Stifel Nicolaus

$190

Buy

5.22%

Upside

Reiterated

10/16/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK), Crescent Biopharma (NASDAQ: CBIO) and Glaukos (NYSE: GKOS)

Anthony Petrone

Mizuho Securities

$185

Buy

2.45%

Upside

Reiterated

10/13/26

Glaukos price target raised to $190 from $185 at MizuhoGlaukos price target raised to $190 from $185 at Mizuho

Adam Maeder

Piper Sandler

$195

Buy

7.99%

Upside

Reiterated

10/12/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Glaukos (NYSE: GKOS)

Ryan Zimmerman

BTIG

$202→$205

Buy

13.53%

Upside

Reiterated

10/12/26

Glaukos price target raised to $205 from $202 at BTIGGlaukos price target raised to $205 from $202 at BTIG

Michael Sarcone

Jefferies

$210

Buy

16.30%

Upside

Reiterated

09/22/26

Glaukos price target raised to $210 from $190 at JefferiesGlaukos price target raised to $210 from $190 at Jefferies

Joanne Wuensch

Citi

$188→$225

Buy

24.61%

Upside

Reiterated

08/14/26

Glaukos (GKOS) Gets a Buy from Citi

Allen Gong

J.P. Morgan

$200

Buy

10.76%

Upside

Reiterated

08/04/26

Glaukos (GKOS) Gets a Buy from J.P. Morgan

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), Viking Therapeutics (NASDAQ: VKTX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

$180→$215

Buy

19.07%

Upside

Reiterated

07/30/26

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

$138→$178

Buy

-1.42%

Downside

Assigned

07/30/26

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

David Saxon

Needham

$150→$201

Buy

11.31%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Glaukos (NYSE: GKOS) and MannKind (NASDAQ: MNKD)

Patrick Wood

UBS

$150→$172

Hold

-4.75%

Downside

Reiterated

07/30/26

Glaukos assumed with Neutral from Buy at UBSGlaukos assumed with Neutral from Buy at UBS

Yi Chen

H.C. Wainwright

$168→$195

Buy

7.99%

Upside

Reiterated

07/30/26

Glaukos price target raised to $195 from $168 at H.C. WainwrightGlaukos price target raised to $195 from $168 at H.C. Wainwright

David Roman

Goldman Sachs

$153

Buy

-15.27%

Downside

Reiterated

05/25/26

Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)

Mason Carrico

Stephens

$115→$145

Buy

-19.70%

Downside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

HROWHarrow Health

KURAKura Oncology

DNLIDenali Therapeutics

STOKStoke Therapeutics

CELCCelcuity

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

3 Months

Allen GongJ.P. Morgan

Success Rate

14/16 ratings generated profit

Average Return

+11.00%

Copying Allen Gong's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +11.00% per trade.

1 Year

Adam MaederPiper Sandler

Success Rate

14/15 ratings generated profit

Average Return

+55.17%

Copying Adam Maeder's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +55.17% per trade.

2 Years

David SaxonNeedham

Success Rate

24/24 ratings generated profit

Average Return

+67.83%

Copying David Saxon's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +67.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GKOS Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GKOS has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GKOS average Analyst price target in the past 3 months is 197.58.

Each month's total comprises the sum of three months' worth of ratings.

GKOS Financial Forecast

GKOS Earnings Forecast

Next quarter’s earnings estimate for GKOS is -$0.10 with a range of -$0.18 to -$0.03. The previous quarter’s EPS was -$0.14. GKOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Sales Forecast

Next quarter’s sales forecast for GKOS is $168.04M with a range of $160.13M to $174.00M. The previous quarter’s sales results were $185.61M. GKOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GKOS has Performed in-line its overall industry.

GKOS Stock Forecast FAQ

What is GKOS’s average 12-month price target, according to analysts?

Based on analyst ratings, Glaukos’s 12-month average price target is 197.58.

What is GKOS’s upside potential, based on the analysts’ average price target?

Glaukos has 9.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GKOS a Buy, Sell or Hold?

Glaukos has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Glaukos’s price target?

The average price target for Glaukos is 197.58. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $225.00 ,the lowest forecast is $172.00. The average price target represents 9.42% Increase from the current price of $180.57.

What do analysts say about Glaukos?

Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of GKOS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Glaukos (GKOS) Stock Forecast & Price Target

GKOS Analyst Ratings

GKOS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Glaukos

GKOS Analyst Recommendation Trends

GKOS Financial Forecast

GKOS Earnings Forecast

GKOS Sales Forecast

GKOS Stock Forecast FAQ

Detailed List of Analyst Forecasts